Kymab Receives $40 Million Investment From Gates Foundation and Wellcome Trust

Kymab, a monoclonal antibody biopharmaceutical company, has raised $40 million in a Series B financing. The Bill & Melinda Gates Foundation joins existing investor, the Wellcome Trust, each investing $20 million.

The funds will enable Kymab to increase the potential of its kymouse platform and advance its pipeline of therapeutic human monoclonal antibodies in areas of unmet medical need. Kymab will also collaborate with the Gates Foundation and its partners on vaccine antigen discovery R&D with a focus on malaria and HIV. Recent data published in Nature Biotechnology demonstrates that the kymouse technology yields an antibody library constituted from 100 trillion different antibodies, in which rare high-quality antibodies can be selected and developed into therapeutics.

In addition, Kymab will pursue a limited number of collaborations to identify and develop therapeutic antibodies in a range of diseases. Kymab has also developed Kymab Access, a program that enables academic researchers to pursue the discovery and development of novel human monoclonal antibody therapeutics and vaccines by partnering with Kymab and its kymouse antibody technology.